Table 2.
Overall response.
| Best response | TAS102 plus BEV | % | TAS102 monotherapy | % | Regorafenib | % | p value |
|---|---|---|---|---|---|---|---|
| n = 139 | n = 153 | n = 53 | |||||
| PR | 8 | (5.8) | 2 | (1.3) | 0 | (0.0) | |
| SD | 81 | (58.3) | 72 | (47.1) | 49 | (36.8) | |
| PD | 47 | (33.8) | 74 | (48.4) | 75 | (56.4) | |
| NE | 3 | (2.2) | 5 | (3.3) | 9 | (6.8) | |
| ORR | 8 | (5.8) | 2 | (1.3) | 0 | (0.0) | 0.005 |
| DCR | 89 | (64.0) | 74 | (50.0) | 49 | (39.5) | <0.001 |
p values were calculated using the Fisher’s exact probability test for categorical variables.
BEV, bevacizumab; DCR, disease control rate; NE, not evaluated; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.